Sanofi Aktie

92,38 EUR -1,82 EUR -1,93 %

21:30:06

STU

92,32 EUR -4,30 EUR -4,45 %

17:50:05

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.116,79 Mrd. EUR

KGV21,10Div. Rendite4,18%

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

Sortieren:Datum Meistgelesen

24.06.22GlobeNewswirePress Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine

13.06.22GlobeNewswirePress Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron

08.06.22GlobeNewswireSanofi launches its first Digital Accelerator fueled by new talent and focused on growth

07.06.22GlobeNewswirePress Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

07.06.22PR NewswireFDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

07.06.22GlobeNewswireSanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people

02.06.22GlobeNewswirePress Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)

01.06.22PR NewswireSobi: FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A

01.06.22GlobeNewswirePress Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A

31.05.22GlobeNewswirePress Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis

31.05.22PR NewswireFDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis

30.05.22GlobeNewswirePress Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial

20.05.22PR NewswireFDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

20.05.22GlobeNewswirePress Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

15.05.22GlobeNewswirePress Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy

11.05.22GlobeNewswirePress Release: New nirsevimab data analyses reinforce efficacy against RSV

16.06.20ReutersSanofi to invest 610 millions euros at two French vaccines sites

11.06.20ReutersHealthcare group Sanofi upbeat on Dupixent opportunities

03.06.20ReutersSanofi to run consultations over restart of hydroxychloroquine trials

29.05.20ReutersExclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials

29.05.20ReutersExclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials amid safety concerns

27.05.20ReutersDrugmaker Sanofi to raise over $11 billion via sale of Regeneron shares

26.05.20ReutersSanofi shares down despite $13 billion Regeneron payday

25.05.20ReutersUPDATE 1-Regeneron to buy back $5 billion stake held by Sanofi

25.05.20ReutersU.S.' Regeneron to buy back $5 billion stake held by Sanofi

25.05.20ReutersU.S.' Regeneron to buy back $5 bln stake held by Sanofi

25.05.20ReutersSanofi to sell stake in Regeneron

15.05.20ReutersSanofi says COVID-19 vaccine will be available worldwide simultaneously

14.05.20ReutersFrance's Macron to meet Sanofi chief on May 19 - Elysee

14.05.20ReutersSanofi says COVID-19 vaccine will be available worldwide simultaneously

14.05.20ReutersSanofi CEO pledges virus vaccine for all after French backlash

14.05.20ReutersUPDATE 3-Sanofi CEO pledges virus vaccine for all after French backlash

14.05.20ReutersFrance says any Sanofi COVID-19 vaccine for the world, no favourites

14.05.20ReutersWRAPUP 1-France says any Sanofi COVID-19 vaccine for the world, no favourites

14.05.20ReutersUPDATE 1-Sanofi CEO says any coronavirus vaccine should reach all regions

14.05.20ReutersSanofi CEO says any coronavirus vaccine should reach all regions

14.05.20ReutersFrance says equal access to any Sanofi virus vaccine is non-negotiable

14.05.20ReutersUPDATE 2-France says equal access to any Sanofi virus vaccine is non-negotiable

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.